



Sheet 1 of 10

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. BMS-2442/ DM-7007 DIV	Application No. 10/663,090
		Applicant Shuang Liu	
		Filing Date September 15, 2003	Group Not Yet Assigned 1616
		Confirmation No. Not Yet Assigned	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
PA	1	Arap, W., et al., "Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model," <i>Science</i> , January 16, 1998, 279, 377-380	
PA	2	Berning, D.E., et al., "Chemical and biomedical motifs of the reactions of hydroxymethylphosphines with amines, amino acids, and model peptides," <i>J. Am. Chem. Soc.</i> , 1999, 121, 1658-1664	
*	3	Bodanszky, "Peptide Chemistry: A Practical Textbook," <i>Springer-Verlag, New York</i> , 1988	
*	4	Bodanszky, et al., "The Practice of Peptide Synthesis," <i>Springer-Verlag, New York</i> , 1984	
PA	5	Bousquet, J.-C., et al., "Gd-DOTA: characterization of a new paramagnetic complex," <i>Radiology</i> , March 1988, 166(3), 693-698	
*	6	Brinkley, M., <i>Bioconjugate Chem.</i> , 1992	
PA	7	Burgess, K., et al., Synthesis and solution conformation of cyclo[RGDRGD]: a cyclic peptide with selectivity for the $\alpha V\beta 3$ receptor," <i>J. Med. Chem.</i> , 1996, 39, 4520-4526	
✓	8	Burke, T.R., Jr., "Protein-tyrosine kinase inhibitors," <i>Drugs of the Future</i> , 1992, 17(2), 119-131	
✓	9	Chang, C.-J., et al., "Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents," <i>J. of Nat. Prod.</i> , November 1992, 55(11), 1529-1560	
PA	10	Cheung, S.T., et al., "N-methylamino acids in peptide synthesis. V. The synthesis of N-tert-butyloxycarbonyl,N-methylamino acids by N-methylation," <i>Can. J. Chem.</i> , 1977, 55, 906-910	
EXAMINER		DATE CONSIDERED 1/28/05	

\* Copies of these references will not be forwarded to the U.S. Patent and Trademark Office since they are believed to be too voluminous and easily obtainable by the Examiner.





<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. BMS-2442/ DM-7007 DIV	Application No. 10/663,090
	Applicant Shuang Liu	
	Filing Date September 15, 2003	Group Not Yet Assigned 10/0
	Confirmation No. Not Yet Assigned	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>		
	11	Corbett, J.W., et al., "Solid-phase synthesis of a selective $\alpha_3\beta_1$ integrin antagonist library," <i>Biorg. &amp; Med. Chem. Letts.</i> , 1997, 7(11), 1371-1376
	12	Cosic, I., et al., "In vitro inhibition of the actions of basic FGF by a novel 16 amino acid peptide," <i>Molecular and Cell. Biochem.</i> , 1994, 130, 1-9
	13	DeGrado, W.F., et al., "Polymer-bound oxime esters as supports for solid-phase peptide synthesis. Preparation of protected peptide fragments," <i>J. Org. Chem.</i> , 1980, 45, 1295-1300
	14	Dougher, A.M., et al., "Identification of a heparin binding peptide on the extracellular domain of the KDR VEGF receptor," <i>Growth Factors</i> , 1997, 14, 257-268
	15	Fischman, A.J., et al., "Infection imaging with technetium-99m-labeled chemotactic peptide analogs," <i>Semin. Nuc. Med.</i> , April 1994, 24(2), 154-168
	16	Freidinger, R.M., et al., "Synthesis of 9-fluorenylmethyloxycarbonyl-protected N-alkyl amino acids by reduction of oxazolidinones," <i>J. Org. Chem.</i> , 1983, 48, 77-81
	17	Fry, D.W., "Protein tyrosine kinases as therapeutic targets in cancer chemotherapy and recent advances in the development of new inhibitors," <i>Exp. Opin. Invest. Drugs</i> , 1994, 3(6), 577-595
	18	Gho, Y.S., et al., "Development of antiangiogenin peptide using a phage-displayed peptide library," <i>Cancer Research</i> , September 1, 1997, 57, 3733-3740
*	19	Greene, "Protective Groups in Organic Synthesis," <i>John Wiley &amp; Sons, New York</i> , 1981
*	20	Greene, "The Peptides: Analysis, Synthesis, Biology," <i>Academic Press, New York</i> , 1981, Vol. 3-
EXAMINER		DATE CONSIDERED 1/28/05

\* Copies of these references will not be forwarded to the U.S. Patent and Trademark Office since they are believed to be too voluminous and easily obtainable by the Examiner.



Sheet 3 of 10

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. BMS-2442/ DM-7007 DIV	Application No. 10/663,090
		Applicant Shuang Liu	
		Filing Date September 15, 2003	Group <del>Not Yet Assigned</del> 1614
		Confirmation No. <del>Not Yet Assigned</del>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	21	Gross, et al. (Eds.), "The Peptides: Analysis, Synthesis, Biology," <i>Academic Press, New York, 1980-1987, Vol. 1, 2, 3, 5, and 9</i>	
	22	Hartman, G.D., et al., "Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors," <i>J. Med. Chem.</i> , 1992, 35, 4640-4642	
	23	Haubner, R., et al., "Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the $\alpha_v\beta_3$ integrin for a new cancer therapy," <i>Angew. Chem. Int. Ed. Engl.</i> , 1997, 36, 1374-1389	
	24	Jardines, L., et al., "neu(c-erbB-2/HER2 and the epidermal growth factor receptor (EGFR) in breast cancer," <i>Pathobiology</i> , 1993, 61, 268-282	
	25	Kolinski, R.A., et al., "Ring inversion in plicyclic tetraamines," <i>Tetrahedron Letts.</i> , 1981, 22(23), 2217-2220	
	26	Maier, L., et al., "Organische phosphorverbindungen 72 Herstellung und eigenschaften von bis(N-hydroxycarbonylmethylamino-methyl)phosphinsäure, (HO <sub>2</sub> CCH <sub>2</sub> NHCH <sub>2</sub> ) <sub>2</sub> P(O)OH, und derivaten," <i>Phosphorus and Sulfur</i> , 1980, 8, 67-72 (English abstract)	
	27	Margerstadt, M., et al., "Gd(DOTA): An alternative to Gd(DTPA) as a T <sub>1,2</sub> relaxation agent for NMR imaging or spectroscopy," <i>Magn. Reson. Med.</i> , 1986, 3, 808-812	
	28	Märkl, V.G., et al., "1,5-diaza-3,7-diphospha-cyclooctane," <i>Tetrahedron Letts.</i> , 1980, 21, 1409-1412	
	29	Merrifield, R.B., "Solid phase peptide synthesis, I. The synthesis of a tetrapeptide," <i>J. Am. Chem. Soc.</i> , 1963, 85, 2149-2154	
	30	Nanda, K.K., et al., "Magneto-structure correlations in macrocyclic dinicke(II) complexes: tuning of spin exchange by varying stereochemistry and auxiliary ligands," <i>Inorg. Chem.</i> , 1994, 33, 1188-1193	
EXAMINER		DATE CONSIDERED 1/28/05	

\* A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.



Sheet 4 of 10

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. BMS-2442/ DM-7007 DIV	Application No. 10/663,090
		Applicant Shuang Liu	
		Filing Date September 15, 2003	Group Not Yet Assigned 1616
		Confirmation No. Not Yet Assigned	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	31	Ortega, N., et al., "Systemic activation of the vascular endothelial growth factor receptor KDR/flk-1 selectively triggers endothelial cells with an angiogenic phenotype," <i>Amer. J. of Pathol.</i> , November 1997, 151(5), 1215-1224	
	32	Osapay, G., et al., "synthesis of tyrocidine A: use of oxime resin for peptide chain assembly and cyclization," <i>Tetrahedron Letts.</i> , 1990, 31(43), 6121-6124	
	33	Pierschbacher, M.D., et al., "Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion," <i>J. of Biol. Chem.</i> , December 25, 1987, 262(36), 17294-17298	
	34	Remington's Pharmaceutical Sciences, 17 <sup>th</sup> Ed., Mack Publishing Co., Easton, PA, 1985, page 1418	
	35	Rewcastle, G.W., et al., "Tyrosine kinase inhibitors. 5. Synthesis and structure - activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor," <i>J. Med. Chem.</i> , 1995, 38, 3482-3487	
	36	Roberts, D.C., et al., "Unusual amino acids in peptide synthesis," <i>The Peptides Analysis, Synthesis, Biology</i> , Gross, E., et al. (Eds.), 1983, Vol. 5, Chap. 6, 341-449	
	37	Runge, V.M., et al., "MR imaging of rat brain glioma: Gd-DTPA versus Gd-DOTA," <i>Radiology</i> , 1988, 166, 835-838	
	38	Senger, D.R., et al., "Angiogenesis promoted by vascular endothelial growth factor: regulation through $\alpha_1\beta_1$ and $\alpha_2\beta_1$ integrins," <i>Proc. Natl. Acad. Sci. USA</i> , December 1997, 94, 13612-13617	
	39	Singh, P.R., et al., "Transition metal chemistry of main group hydrazides. Part 3: Carboxylate appended phosphorus hydrazides as novel functionalized chelating systems. Synthesis and characterization of new cyclometallaphosphohydrazides. X-ray structure of a palladium(II) representative," <i>Inorg. Chem.</i> , 1994, 33, 736-741	
	40	Singh, P.R., et al., "Transition metal chemistry of main group hydrazides, Part 14: Evaluation of new Tc-99m chelates of thiol functionalized phosphorus hydrazides," <i>Nucl. Med. Biol.</i> , 1995, 22(7), 849-857	
EXAMINER			DATE CONSIDERED 1/28/05






Sheet 5 of 10

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. BMS-2442/ DM-7007 DIV	Application No. 10/663,090
		Applicant Shuang Liu	
		Filing Date September 15, 2003	Group <del>Not Yet Assigned</del> 1610
		Confirmation No. <del>Not Yet Assigned</del>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	41	Soker, S., et al., "Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF <sub>165</sub> ," <i>J. of Biol. Chem.</i> , 1997, 272(50), 31582-31588	
	42	Srivatsa, S.S., et al., "Selective $\alpha v \beta 3$ integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin $\alpha v \beta 3$ and osteopontin expression during neointimal formation," <i>Cardiovascular Res.</i> , 1997, 36, 408-428	
*	43	Steward, et al., "Solid Phase Peptide Synthesis," 2 <sup>nd</sup> ed., <i>Pierce Chemical Co., Rockford, IL</i> , 1984	
	44	Taliaferro, C.H., et al., "New multidentate ligands. 22. <i>N,N'</i> -dipyridoxylethylenediamine- <i>N,N'</i> -diacetic acid: a new chelating ligand for trivalent metal ions," <i>Inorg. Chem.</i> , 23, 1188-1192	
	45	Thompson, A.M., et al., "Tyrosine kinase inhibitors. 13. Structure - activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3- <i>d</i> ]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor," <i>J. Med. Chem.</i> , 1997, 40, 3915-3925	
	46	Tramotini, M., et al., "Tetrahedron Report Number 271," <i>Tetrahedron</i> , 1990, 1791-1827	
	47	Tramotini, M., "Advances in the Chemistry of mannich bases," <i>Synthesis</i> , December 1976, 703-775	
	48	Tran, T.-A., et al., "A novel RGD containing dodecapeptidomimetic which exhibits selective binding to the $\alpha_v \beta_3$ receptor," <i>Bioorg. &amp; Med. Chem. Lett.</i> , 1997, 7(8), 997-1002	
	49	Varga, T.R., "Synthesis of bis(aminomethyl)-phosphinic acids via a mannich reaction," <i>Synthetic Communication</i> , 1997, 27(17), 2899-2903	
	50	Weisman, G.R., et al., "Tetracyclic tetraamines by glyoxal-macrocyclic tetraamine condensation," <i>Tetrahedron Letts.</i> , 1980, 21, 335-338	
EXAMINER		DATE CONSIDERED 1/28/05	

\* A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.



Sheet 6 of 10

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. BMS-2442/ DM-7007 DIV	Application No. 10/663,090
	Applicant Shuang Liu	
	Filing Date September 15, 2003	Group <del>Not Yet Assigned</del> 10/6
	Confirmation No. <del>Not Yet Assigned</del>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>		
	51	Wu, P.-L., et al., "1-acyl-2-alkylhydrazines by the reduction of acylhydrazones," <i>Synthesis</i> , April 1995, 435-438
	52	Yayon, A., et al., "Isolation of peptides that inhibit binding of basic fibroblast growth factor to its receptor from a random phage-epitope library," <i>Proc. Natl. Acad. Sci. USA</i> , November 1993, 90, 10643-10647
<b>EXAMINER</b> 	<b>DATE CONSIDERED</b> 1/28/05	



Sheet 7 of 10

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. BMS-2442/ DM-7007 DIV	Application No. 10/663,090		
		Applicant Shuang Liu			
		Filing Date September 15, 2003	Group <del>Not Yet Assigned</del> 1616		
		Confirmation No. <del>Not Yet Assigned</del>			
<b>U. S. PATENT DOCUMENTS</b>					
Examiner Initial	Document No.	Date	Name	Class	Subclass
TS	53	5,730,787	03/24/98	Kasai	—
	54	4,427,646	01/24/84	Olexa, et al.	424 1.1
	55	4,578,079	03/25/86	Ruoslahti, et al.	623 11
	56	4,792,525	12/20/88	Ruoslahti, et al.	435 240.243
	57	5,086,069	02/04/92	Klein, et al.	514 399
	58	5,087,440	02/11/92	Cacheris, et al.	424 9
	59	5,155,215	10/13/92	Ranney	534 16
	60	5,217,705	06/08/93	Reno, et al.	424 1.1
	61	5,270,030	12/14/93	Vogel, et al.	424 9
	62	5,277,892	01/11/94	Rhodes	424 1.69
	63	5,279,812	01/18/94	Krstenansky, et al.	424 1.1
	64	5,536,814	07/16/96	Ruoslahti, et al.	530 329
	65	5,766,591	06/16/98	Brooks, et al.	424 184.1
	66	5,767,071	06/16/98	Palladino, et al.	514 11
	67	5,770,565	06/23/98	Cheng, et al.	514 11
TS	68	5,780,426	07/14/98	Palladino, et al.	514 9
EXAMINER <i>TS Jones</i>			DATE CONSIDERED 1/30/05		



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. BMS-2442/ DM-7007 DIV	Application No. 10/663,090				
		Applicant Shuang Liu					
		Filing Date September 15, 2003	Group <del>Not Yet Assigned</del> 1616				
		Confirmation No. Not Yet Assigned					
<b>U. S. PATENT DOCUMENTS</b>							
Examiner Initial		Document No.	Date	Name	Class	Subclass	
	69	5,792,444	08/11/98	Fischman, et al.	424	1.69	
	70	5,879,657	03/09/99	DeGrado, et al.	424	1.69	
	71	5,880,281	03/09/99	Argese, et al.	540	474	
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initial		Document No.	Date	Country	class/Subcls	Translation	
	X 72	WO 88/07048	09/22/88	PCT	—	YES	NO
	X 73	WO 94/03464	02/17/94	PCT	—		
	X 74	WO 94/26275	11/24/94	PCT	—		
	X 75	WO 95/28968	11/02/95	PCT	—		
	76	WO 89/05150	06/15/89	PCT	—		
	77	WO 89/10135	11/02/89	PCT	—		
<b>EXAMINER</b>				<b>DATE CONSIDERED</b> 1/28/05			




<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office				Docket No. BMS-2442/ DM-7007 DIV		Application No. 10/663,090	
				Applicant Shuang Liu			
				Filing Date September 15, 2003		Group <del>Not Yet Assigned</del> 1616	
				Confirmation No. <del>Not Yet Assigned</del>			
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initial		Document No.	Date	Country	Class/subclass	Translation	
						YES	NO
	78	WO 90/00178	01/11/90	PCT			
	79	WO 90/03391	04/05/90	PCT	—		
	80	WO 90/15818	12/27/90	PCT	—		
	81	WO 91/01331	02/07/91	PCT	—		
	82	WO 91/15515	10/17/91	PCT	—		
	83	WO 92/13572	08/20/92	PCT	—		
	84	WO 93/12819	07/08/93	PCT	—		
	85	WO 93/17719	09/16/93	PCT	—		
	86	WO 93/23085	✓ 11/25/93	PCT	—		
	87	WO 94/00489	✓ 01/06/94	PCT	—		
	88	WO 94/05269	✓ 03/17/94	PCT	—		
	89	WO 95/14726	✓ 06/01/95	PCT	—		
	90	WO 98/15295	✓ 04/16/98	PCT	—		
	91	0 398 143 A1	✓ 11/22/90	EPO	—		
	92	0 410 537 A1	✓ 01/30/91	EPO	—		
	93	0 410 541 A1	✓ 01/30/91	EPO	—		
	94	0 422 937 A1	✓ 04/17/91	EPO	—		
<b>EXAMINER</b>				<b>DATE CONSIDERED</b> 1/28/05			



Sheet 10 of 10

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office				Docket No. BMS-2442/ DM-7007 DIV		Application No. 10/663,090	
				Applicant Shuang Liu			
				Filing Date September 15, 2003		Group Not Yet Assigned 16/4	
				Confirmation No. Not Yet Assigned			
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initial		Document No.	Date	Country	class/subclass	Translation	
						YES	NO
	95	0 422 938 A1 ✓	4/17/91	EPO	—		
	96	0 425 212 A3 ✓	05/02/91	EPO	—		
	97	0 478 328 B1 ✓	04/01/92	EPO	—		
	98	226,849 A1 ✓	01/08/25	Great Britain	—		
	99	2 225 579 A	06/06/90	Great Britain	—		
<b>EXAMINER</b> R. Jones				<b>DATE CONSIDERED</b> 1/28/05			



Sheet 1 of 2

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. BMS-2442	Application No. 10/663,090
	Applicant Shuang Liu	
	Filing Date September 15, 2003	Group <del>Not Yet Assigned</del> 1618
	Confirmation No. <del>Not Yet Assigned</del>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>		
	1	Copy of the EPO Search Report dated September 15, 2003 (EP 03 07 7312)
EXAMINER	DATE CONSIDERED 1/28/05	



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. BMS-2442	Application No. 10/663,090
	Applicant Shuang Liu	
	Filing Date September 15, 2003	Group <del>Not Yet Assigned</del> 1616
	Docket No. BMS-2442	Application No. 10/663,090

**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass
DA	2	5,730,787	03/24/98	Kasai, et al.	106	2

**FOREIGN PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Country	Class/Subclass	Translation	
						YES	NO
DA	3	WO 88/07048	09/22/88	PCT	—	X abstract	
	4	WO 95/28968	11/02/95	PCT	—		
	5	WO 94/03464	02/17/94	PCT	—		
DA	6	WO 94/26275	11/24/94	PCT	—		

EXAMINER *DA* DATE CONSIDERED 1/28/05